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Abstract
Human cancer is caused by the accumulation of genetic alterations in cells. Of special importance are changes that occur
early during malignant transformation because they may result in oncogene addiction and thus represent promising targets
for therapeutic intervention. We have previously described a computational approach, called Retracing the Evolutionary
Steps in Cancer (RESIC), to determine the temporal sequence of genetic alterations during tumorigenesis from cross-
sectional genomic data of tumors at their fully transformed stage. Since alterations within a set of genes belonging to a
particular signaling pathway may have similar or equivalent effects, we applied a pathway-based systems biology approach
to the RESIC methodology. This method was used to determine whether alterations of specific pathways develop early or
late during malignant transformation. When applied to primary glioblastoma (GBM) copy number data from The Cancer
Genome Atlas (TCGA) project, RESIC identified a temporal order of pathway alterations consistent with the order of events
in secondary GBMs. We then further subdivided the samples into the four main GBM subtypes and determined the relative
contributions of each subtype to the overall results: we found that the overall ordering applied for the proneural subtype
but differed for mesenchymal samples. The temporal sequence of events could not be identified for neural and classical
subtypes, possibly due to a limited number of samples. Moreover, for samples of the proneural subtype, we detected two
distinct temporal sequences of events: (i) RAS pathway activation was followed by TP53 inactivation and finally PI3K2
activation, and (ii) RAS activation preceded only AKT activation. This extension of the RESIC methodology provides an
evolutionary mathematical approach to identify the temporal sequence of pathway changes driving tumorigenesis and may
be useful in guiding the understanding of signaling rearrangements in cancer development.
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Introduction
New high-throughput sequencing and microarray technologies
provide researchers with access to increasingly large and complex
datasets comprising genome-level alterations in cancer [1,2,3].
Computational algorithms have been designed to sift through this
data with the goal of uncovering mutational patterns that are
typical for a particular cancer type and consistent between sample
sets [1,2,4,5]. However, the ability to functionally validate
recurrent genetic events in transgenic mouse models and human
cell lines is limited by the lack of knowledge of the temporal order
in which these alterations arise during tumorigenesis. The
temporal sequence of events is important since it can inform the
correct genomic background in which a mutation must arise to
confer an oncogenic phenotype to cells. Furthermore, it may
contribute to drug discovery since genomic alterations arising early
during tumorigenesis may be more likely to induce oncogenic
addiction and may thus represent promising therapeutic targets
[6]. In some cancers, such as colorectal cancer, the order of events
can be determined through the analysis of several pre-malignant
stages [7,8]. Most cancer types, however, do not present with
clinically observable precursor stages, and therefore the identifi-
cation of the temporal sequence of events using biological or
clinical approaches is difficult.
There is a growing literature of mathematical, statistical and
computational approaches to determining the temporal sequence
of events arising during tumorigenesis. Previously published
methods include the linear model [7], the oncogenetic tree
PLoS Computational Biology | www.ploscompbiol.org 1 January 2012 | Volume 8 | Issue 1 | e1002337(oncotree) approach [9,10,11,12], various Bayesian graphical
approaches [13,14], and some clustering-based methods [15,16].
Based upon the seminal work in delineating the temporal sequence
of events in colorectal cancer by Vogelstein and colleagues, the
linear model assumes that there exists a single, most likely order of
mutations, and that all of these mutations arise in sequential order
[7]. The oncogenetic tree approach generalizes the assumption of
a single sequential path by providing a tree structure to the
temporal sequence of mutations, allowing for diverging temporal
orderings of events [9,10]. In probabilistic oncotrees, the tree
structure represents the probabilities of accumulating further
mutations along divergent temporal sequences [9]. An alternative
distance-based oncotree approach involves generating a phyloge-
netic tree over all events using a distance measure between
mutational events, where leaf nodes represent the set of possible
events. The closer a leaf node is to the root, the earlier the
corresponding mutation arises [10]. Further development of the
probabilistic oncotree methodology by Beerenwinkel et al. resulted
in the mixture tree model, in which multiple oncogenetic trees,
each of which can result in cancer development independently, are
included in the model [12]. The consideration of multiple tree
structures allows for inclusion of multiple independent temporal
sequences of events that can result in the development of cancer.
Notably, one tree structure that the mixture tree model includes is
a star-shaped tree predicting that every mutation arises indepen-
dently, accounting for random mutations that arise but are not
involved in any temporal sequence of events. An expectation
maximization algorithm is then used to determine the most likely
tree mixture to fit the data [12]. This approach has often been
used to analyze CGH data [17,18,19,20,21,22,23]. However, one
acknowledged restriction of tree-based methods is that the tree
structure precludes the possibility of converging evolutionary paths
[13] that occur when multiple alterations result in the same
phenotypic effect. Furthermore, tree-based models impose a strict
ordering of events: if an event occurs in a leaf of the tree, then it
necessarily must be preceded by all events between the leaf and the
root of the tree. Bayesian graphical methods, by allowing any
network structure, can include converging evolutionary paths
[13,14], however at the cost of additional computation necessary
to search the expanded multi-dimensional result space.
We have previously described a computational approach, called
Retracing the Evolutionary Steps In Cancer (RESIC) [24], which
determines the temporal sequence of specific genetic events for
primary tumor types for which cross-sectional genomic data is
available (Figure 1A). This approach can be used to resolve the
relative order of genetic events with respect to other alterations of
interest; however, in the absence of further data, the time of
emergence of these events relative to phenotypes such as
malignancy or metastasis cannot be identified. In the RESIC
model, we adopted a different approach as compared to prior
work: RESIC explicitly considers the evolutionary dynamics of
mutation accumulation within a population of patients. Each
patient harbors a collection of self-renewing cells that are at risk of
accumulating the alterations leading to cancer; this cell population
follows a stochastic process known as the Moran model [25]. This
stochastic process model of mutation accumulation was then
approximated with a dynamical systems model whose steady state
distribution across all possible mutational states can be compared
with the frequencies of patients harboring the corresponding
genetic events. The resulting fitness values conferred by genomic
alterations, obtained by an optimization algorithm to minimize the
distance between the observed and predicted patient frequencies,
were then used to determine the relative order of events arising in
a patient population [24]. RESIC analyses are performed for sets
of correlated genetic events, thus resulting in a relative ordering of
alterations. The use of pair-wise comparisons also allows for
converging temporal orderings. A detailed explanation of the
RESIC algorithm is provided in the Methods section.
In many cases, specific genetic alterations are not necessary for
malignant transformation; instead, particular oncogenic pheno-
types must be achieved through the emergence of any of a number
of alternative mutations (Figure 1B) [26,27,28,29,30]. In addition,
many cancers can be subdivided into distinct molecular subtypes
(Figure 1C), which often result from differences in the set of
genetic alterations accumulated and potentially the order in which
they arise. Including pathway and subtyping information may alter
the order in which genetic events arise during cancer progression.
To address these issues, we have extended our RESIC
methodology to consider both pathway-based phenotypic changes
and the subtype-driven context of cancer in order to examine how
the temporal sequence of events differs when such information is
included. These two topics are considered in the analysis of
primary glioblastoma (GBM). Due to its aggressiveness and poor
prognosis, as well as its frequency, patient samples of GBM have
been extensively collected and the data made easily accessible to
researchers. In particular, The Cancer Genome Atlas (TCGA)
project has provided measurements of multiple types of genomic
alterations, with each sample processed in a uniform manner, for a
large set of patient samples of GBMs [3]. The TCGA dataset
provides an opportunity to effectively analyze the temporal
sequence of pathway alterations using RESIC through an
investigation of the specific signaling disruptions common to
GBMs [31,32], its well-defined molecular subtypes [33,34,35], and
the availability of similarly treated patient samples [3]. We chose
the RESIC methodology instead of previous approaches to
investigate these issues since RESIC provides, in addition to the
temporal ordering of events, the relative fitness values of cells
harboring individual combinations of mutations. Furthermore,
RESIC is capable of determining the order of different types of
events, such as point mutations, focal amplifications and deletions,
Author Summary
Cancer is a deadly disease that develops through the
accumulation of genetic changes over time. Many
biological models do not incorporate this temporal aspect
of tumor formation and progression, in part due to the
difficulty of determining the sequence of events through
biological experimentation for most cancer types. We
previously developed a computational algorithm with
which we can quickly and cost-effectively determine the
order in which mutations arise in the tumor even when
large numbers of mutations are considered. In this paper,
we extended our method to incorporate biological
knowledge of the common pathways by which cancer
progresses. We applied these techniques to primary
glioblastoma, the most common form of brain cancer.
We found that when all samples are taken into account, a
temporal sequence of pathway events emerges; however,
different subtypes of glioblastoma vary in their temporal
sequence of events. This algorithm can also be easily
applied to other cancer types as clinical data becomes
available, showing the benefit of computational and
mathematical tools in cancer research. Using temporal
information, cancer biologists will be able to develop more
accurate animal models of tumor formation and learn
more about how mutations interact in time, thus leading
to better treatments for cancer.
Determining the Order of Pathway Alterations
PLoS Computational Biology | www.ploscompbiol.org 2 January 2012 | Volume 8 | Issue 1 | e1002337Figure 1. The methodology of pathway-driven RESIC. A) A schematic diagram of pathway-driven RESIC. For those cancer types for which
clinico-pathologically defined stages can be identified, such as colorectal cancer, the temporal sequence in which genetic alterations arise during
tumorigenesis can be inferred through genotyping of samples from patients at different stages of disease progression. We previously designed an
Determining the Order of Pathway Alterations
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Finally, RESIC is computationally efficient.
Results
Data and parameters
We gathered copy number alteration (CNA) data from 462
GBM patient samples through the TCGA Data portal at http://
tcga-data.nci.nih.gov [3]. We then applied the GISTIC algorithm
[5] to the segmented CNA data in order to determine the
significance of all copy number alterations. In particular, we
applied our method to focal amplifications and deletions, not
whole chromosome alterations, as the former alterations are more
likely to result in the alteration of only a single gene or a few genes.
A subset of the patient samples (431) also included gene expression
data, which we used for subtyping. Roughly a third of the samples
(145) also included sequencing information [3], which we used to
investigate the robustness of the results obtained when using solely
CNA data. For this validation, we limited point mutations of
interest to non-synonymous point mutations and small insertions
or deletions (indels). For all RESIC analyses, we considered
significant positive correlations between events using one-sided
Fisher’s Exact Test with a p-value cutoff of 0.05, as required for
data pre-processing within our RESIC methodology in order to
ensure co-occurrence of events. If mutational events do not co-
occur sufficiently frequently, then the question about the temporal
sequence of events is meaningless since the events may be
associated with separate subtypes [24]. We used an uncorrected p-
value cutoff of 0.05 instead of applying a correction for multiple
testing in order to broaden the set of mutations to be included in
our analyses. We also limited considered interactions to those pairs
of genes with a marginal and joint frequency of alteration greater
than 5%. Since each CNA may span several genes, the
interpretation of results needs to take the identity of those genes
and likely functional effects into account; a straight-forward
interpretation of the results is to assign the obtained order to CNA
events rather than individual genes. Since the genes within one
CNA arose due to a common mechanism and are thus not
independent, no conclusion can be drawn about the causal
implications of each gene within the CAN for its emergence.
RESIC relies upon the transition rates between mutational
states, which are a function of the number of cells at risk of
accumulating the alterations (the population size), the rate at
which the alterations arise (the mutation rate), and the change in
growth rate that alterations confer to cells (the fitness) [24]. In the
RESIC implementation, the optimization algorithm is used to
identify the fitness values that minimize the distance between
model prediction and patient data while keeping the population
size and mutation rate estimates constant [24]. This choice was
made due to the robustness of the results to changes in these latter
parameters [24]. We calculated the rate at which focal CNAs arise
per cell division by using the copy number alteration rate per locus
per generation as determined in sperm, multiplied by the number
of cell divisions during spermatogenesis (see Methods). Using those
estimates, we obtained a CNA rate per locus per cell division of
2.2610
27. This rate agrees with argumentation that point
mutation and focal copy number alteration rates must be similar
in scale in order for both types of alterations to be observed with
similar frequency [36]. We used m=1.0610
27 as the rate at which
CNAs arise per allele per cell division, and N=100 as the
population size for computational speed; while the latter number
may not accurately capture the order of magnitude of the number
of stem cells per tissue compartment from which the tumor
initiates, or the number of cancer stem cells per tumor, we have
previously shown that the results of RESIC are not significantly
affected by changes in the population size by orders of magnitude
[24]. This robustness arises due to the scaling of the transition rates
in the Markov process by the magnitude of the population size and
holds as long as the system parameters are within a regime such
that step-by-step evolution applies (i.e. one mutation arises and is
lost or fixed before the next one emerges, [24]).
RESIC analysis of CNA data provides similar results to
analysis of point mutation and CNA data
To ensure the validity of our analysis using solely CNA data, we
performed separate RESIC analyses of the CNA data alone; these
results were then compared to those obtained using CNA and
point mutation data in the subset of the samples for which both
CNA and point mutation information was available. Similarly to
our prior validation analyses [24], we expected that almost all
orderings determined using CNA information only would either
remain the same or weaken in significance. Indeed, we found that
our results varied little when including point mutation data also.
The only exception involved TP53, a gene known to be primarily
altered through point mutations [37]. In the largest set of cases,
23/40 at the paired-gene level and 3/6 at the pathway level, the
resultant orderings remained within 3% of each other while the
dominant order stayed constant. In a second set of orderings, the
findings decreased in significance when only CNA data was
included (13/40 when analyzed using pairs of genes and 1/6 at the
pathway level). The smallest group involved those orderings that
differed between analyses using CNA data only and analyses using
CNA plus point mutations, with 4/40 using gene-pair comparisons
and 2/6 using pathway analyses. In this group, most orderings (5/
6) involved TP53. The remaining ordering involved the PDGFRA
locus, with point mutations occurring in amplified PDGFRA.
RESIC analyses involving three-gene mutation diagrams were not
significant due to the smaller set of samples available compounded
with the larger number of samples required for three-gene
analysis. Thus, with the exception of genes most commonly
altered by point mutations, the orders determined using CNA
information only are equivalent or weaker than those using point
mutation data and CNA data. As such, use of CNA data alone at
most provides weaker temporal sequences and at best provides
evolutionary computational algorithm called Retracing the Evolutionary Steps In Cancer (RESIC) to determine the temporal order of somatic
mutations for cancer types that are diagnosed de novo without detectable precursor lesions (e.g. primary glioblastoma) through the use of genomic
data from a large number of samples (one per patient) of a particular histological type [24]. We extended this methodology to analyze the temporal
sequence of functional alterations in signaling pathways. We begin with a genomic dataset of patient samples classified as the tumor (sub)type of
interest. As Step 1, we use an algorithm such as GISTIC [5] to identify recurrent genetic aberrations in the dataset. In Step 2, we combine genetic
alterations identified as impacting specific signaling pathways into single alteration events. In Step 3, we identify statistically significantly correlated
events that occur sufficiently frequently. In Step 4, the most likely sequence for each set of associated events is identified using RESIC. The results
generated from the RESIC analyses are used to reconstruct the order in which pathway alteration events arise during the development of a particular
cancer type (Step 5). Our methodology is applicable to large-scale datasets and can be used to identify the temporal sequence of pathway alterations
in cancer. B) Functional modules in signaling result in single events analyzed in RESIC. C) Gene expression-based subtypes can be split up into
separate RESIC analyses or analyzed as a combined dataset.
doi:10.1371/journal.pcbi.1002337.g001
Determining the Order of Pathway Alterations
PLoS Computational Biology | www.ploscompbiol.org 4 January 2012 | Volume 8 | Issue 1 | e1002337equivalent temporal sequences as compared to analyses including
point mutations also, unless a gene is known to be primarily
altered via point mutations.
A pathway-based RESIC analysis of GBM determines a
consistent overall order of events
In many cancer types, a variety of genetic and/or epigenetic
alterations result in a common phenotype required for cancer
initiation and progression. In an effort to categorize the effects of
specific genetic alterations, we classified these changes into the
signaling pathways to which the altered genes belong. This choice
was made since commonly mutated genes that reside in the same
signaling pathway are expected to affect the progression of cancer
in a similar manner; indeed, such commonality in phenotypic
effects has been observed in multiple pathways involved in GBM
[31,38,39,40,41,42]. Therefore, any alteration in the set of genes
within a single signaling pathway is expected to result in the same
(or very similar) effects onto the reproductive success of cells
carrying such alterations. We thus defined a pathway alteration as
an event in which at least one of the genes involved in the pathway
is genetically altered; for our purposes, pathways are defined
following the approach of the TCGA project [3,31,32] (see
Methods for details and a discussion of alternative approaches for
pathway definition). Through the combination of mutational
events into pathways, we are then able to obtain a broad view of
the order of events in cancers in which conflicting signals obscure
the order of events at the single gene level. We considered the
TP53, PI3KC1/AKT, PI3KC2, RAS, and RB signaling pathways
in GBM (Table 1). Inactivation of the TP53 pathway was defined
by amplification of MDM2/4 or deletion of TP53 or CDKN2A;
since sequence information was not available for most samples,
point mutations inactivating TP53 could not be included.
Activation of the PI3KC1/AKT pathway was defined by
amplification of AKT1/2/3, GAB1, IRS1, PIK3CA/B/D/G,
PIK3R1/2, PDPK1, or SRC, or deletion of PTEN. Activation of
the PIK3C2 pathway referred to amplification of PIK3C2A/B/G.
RAS pathway activation was defined by amplification of ARAF/
BRAF/HRAS/KRAS/NRAS, EGFR, ERBB2/3, FGFR1/2,
GRB2, IGFR, MET, PDGFRA/B, or RAF1, or deletion of
CBL, ERRFI1, or SPRY2. RB pathway inactivation referred to
amplification of CCND1/2, CCNE1, or CDK2/4/6, or deletion
of CDKN1A/B, CDKN2A/B/C, or RB1 (Table 1). These
pathways were defined as previously described using the Pathway
Commons approach to investigate TCGA GBM data [31,32].
We then applied the RESIC algorithm to pairs of co-occurring
pathway alterations and determined a general order for signaling
pathway disruptions. When using all GBM samples in a single
computational analysis, we found that RB signaling alteration
occurs early during gliomagenesis. In contrast, AKT and PI3K2
signaling alterations occur late, while RAS and TP53 signaling
changes arise in between the early and late events (Figure 2). As
observed in the CNA-only versus CNA with point mutation
validation analysis, the addition of point mutation information
leads to earlier placement of point mutation-driven alterations.
Thus, TP53 pathway alteration may actually arise earlier, given
that TP53 alteration tends to be due to point mutation. In no case
were these signaling pathway alterations driven primarily by a
single mutation. While the placement of RAS pathway alterations
before AKT/PIK3C1 pathway changes seems to be in contrast to
our previous results involving EGFR (part of the RAS pathway)
and PTEN (included in the AKT/PIK3C1 pathway) [24], in
actuality, the earlier result does not preclude the possibility that
other mutations in the RAS pathway arise even earlier. The
benefit of the pathway-driven approach is that these sporadic
mutations can be combined into a single event for a better
comparison of functional consequences such as (in)activation of
pathway signaling. For the detailed output of the orderings
determined by RESIC for the GBM dataset, see Text S1.
While biological investigations of primary GBMs have not
determined the order in which pathways are altered, the possibility
arises to compare our results to secondary GBMs, for which the
order of events can be inferred from the tumor grade. We thus
compared the results of our RESIC pathway analysis against
literature evidence about the order of events in secondary
glioblastomas. Disruption of RB signaling as an early event is
consistent with both the necessity of passing the G1/S cell cycle
checkpoint to allow the development of a tumor and the
observation of RB pathway mutations in the majority of low-
and high-grade gliomas [43]. While TP53 loss-of-function point
mutations occur in most low-grade gliomas [44,45], our restriction
to solely CNAs excludes such mutations from the analysis. Despite
not including TP53 point mutations in the analysis, we obtained
the results that TP53 pathway alteration occurs early during
tumorigenesis via MDM2 and MDM4 alterations. Inclusion of
point mutations would only increase the frequency of TP53
Table 1. The definition of pathways.
Positive Effects
TP53 PIK3C1/AKT PI3KC2 RAS RB
CDKN2A AKT1 PIK3C2A ARAF CDKN1A
TTP53 AKT2 PIK3C2B BRAF CDKN1B
AKT3 PIK3C2G EGFR CDKN2A
GAB1 ERBB2 CDKN2B
IRS1 ERBB3 CDKN2C
PIK3CA FGFR1 RB1
PIK3CB FGFR2
PIK3CD GRB2
PIK3CG HRAS
PIK3CR1 IGFR
PIK3CR2 KRAS
PDPK1 MET
SRC NRAS
PDGFRA
PDGFRB
RAF1
Negative Effects
TP53 PIK3C1/AKT PI3K2 RAS RB
MDM2 PTEN CBL CCND1
MDM4 ERRFI1 CCND2
SPRY2 CCNE1
CDK2
CDK4
CDK6
We split all genes into those with negative effects on the pathway and those
with positive effects. Each column is headed by the name of the signaling
pathway in which the genes reside, followed by the list of genes. A gene with
positive effect increases the generation of the pathway’s product when
amplified, while a negative effect gene decreases its production when
amplified. Deletion of a gene has the reverse effect on the pathway.
doi:10.1371/journal.pcbi.1002337.t001
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earlier, as seen in our CNA data-only validation analyses. In vitro
studies confirm the positioning of the remaining pathway
alterations: previous results in cell lines showed that AKT signaling
alteration contributes to the progression of anaplastic astrocytomas
to GBMs [46], but cannot initiate tumorigenesis without RAS
activation [47]. Additionally, previous work showed that RB
alteration, TP53 inactivation and hTERT expression in combi-
nation with RAS activation resulted in the malignant transforma-
tion of normal cells; however, the emergence of PI3 kinase
alterations with RB, TP53, and hTERT changes without RAS
alterations were not capable of inducing similar responses [48],
thereby placing both AKT/PIK3C1 and PI3KC2 pathway
alterations relatively late during malignant transformation. These
in vitro studies in secondary GBMs provide independent support
for our results in primary GBMs.
RESIC identifies distinct temporal sequences of pathway
alterations for GBM subtypes
Recent findings demonstrate the existence of distinct molecular
subtypes of GBMs [33,34,35], and we hypothesized that the order
in which pathways alterations arise may vary between subtypes.
We used gene expression profiling following the approach of
Verhaak et al. [35] to cluster GBM samples into the previously
described subtypes. In brief, we used Consensus Clustering, a form
of hierarchical clustering with agglomerative average linkage, to
determine the set of clusters in the gene expression data (Figure 3A
and B) [49]. Positive silhouette widths were then used to identify
the subset of samples that fit well into each subtype (Figure 3C)
[50]. Thus, we obtained 98 samples of the classical subtype, 157 of
the mesenchymal, 43 of the neural, and 120 of the proneural
subtype (see Methods for details). These frequencies of samples in
each subtype were similar to the frequencies determined in
previous studies [5,34,35,51,52]. Additionally, since some previous
subtyping efforts were done utilizing TCGA data, we compared
these results to ours and found a very high concordance (.90%) in
the subtyping of the shared samples [35]. These results implied
that the clusters we determined corresponded to the subtypes
previously determined. By applying our pathway-based RESIC
approach to each of these clustered sets of samples individually, we
then tested whether the temporal order of pathway alterations
detected at the subtype level corresponded to the same or similar
order of events as detected earlier when all samples were analyzed.
Each subtype-specific RESIC analysis was performed in the same
manner as the overall pathway-based GBM analysis (see Methods).
We detected a significant temporal order for the two largest
subtypes (proneural and mesenchymal GBM), some correlations
but no significant order in the second smallest type (classical
GBM), and no correlations in the smallest subtype (neural GBM).
We found distinct differences between the subtypes with significant
temporal sequences, as outlined in the following.
Proneural GBM
The second largest cluster of samples was the proneural subtype
with 120 samples. This subtype is characterized by PDGF-related
amplifications and TP53 point mutations [35]. We found that the
temporal sequence of pathway alterations in this subtype closely
recapitulated the overall pathway order results. The primary
difference between the two was a lack of a significant ordering
involving the RB pathway in this subtype. Additionally, RAS
pathway alteration was placed before TP53 pathway inactivation.
Interestingly, we detected a divergence in the temporal order
between PIK3C1/AKT (AKT1/2/3, GAB1, IRS1, PIK3CA/B/
D/G, PIK3R1/2, PDPK1, SRC, PTEN) and PIK3C2
(PIK3C2A/B/G) signaling (Figure 4A) even though both
pathways involve the lipid-kinase activity of PI3K family enzymes
[53]. In particular, we found that PIK3C2 pathway alterations
require subsequent TP53 pathway inactivation, through alteration
of MDM2/4, TTP53, and/or CDKN2A, while PIK3C1/AKT
alterations do not (Figure 4A). This difference may be explained
through the downstream effects of PIK3C1 signaling: specifically,
in the PIK3 class 1 pathway, PIK3 class 1 family proteins produce
PIP3, which results in downstream activation of AKT and
activation of the MDM2 gene; the latter then inactivates TP53
signaling [53]. By contrast, PIK3 class 2 enzymes catalyze
formation of PI-3-P, which does not activate AKT to inactivate
TP53 signaling [53]. As such, the set of samples with AKT/
PI3KC1 signaling activation may not require TP53 signaling
inactivation while for the set of samples with PIK3C2 activation,
inactivation of the TP53 network may be necessary. Thus, the two
divergent temporal sequences may represent a difference in the
Figure 2. Temporal sequence of pathway alterations in all
samples. Alterations included as alterations of each pathway are
defined in Table 1. Each arrow indicates the order in which the two
alterations arise. The first number represents the frequency with which
the displayed temporal sequence occurs. The second number
represents the percent of all bootstrap iterations in which the order
determined acts as the dominant temporal sequence.
doi:10.1371/journal.pcbi.1002337.g002
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the proneural subtype. For the detailed output of the orders
determined by RESIC for the proneural subtype, see Text S2.
Mesenchymal GBM
The largest GBM subtype was the mesenchymal subtype with
143 samples. Even though this subtype is characterized by NF1
alterations [35], our GISTIC analyses did not detect any
significant copy number alterations of the NF1 locus. Indeed, loss
of the NF1 protein can be driven by multiple mechanisms
including heterozygous copy number changes, inactivating point
mutations, and low levels of gene expression without genomic
alterations [3]. We therefore excluded NF1 from our analysis and
focused on the remaining copy number changes. Unlike the
proneural subtype and in contrast to the overall results derived
from all samples, RESIC predicted that samples of the
mesenchymal subtype first accumulate TP53 pathway inactiva-
tion, followed by PIK3C2 and RB pathway alterations, and
concluding with RAS and PIK3C1/AKT changes (Figure 4B).
One possibility for the early placement of TP53 pathway
inactivation is that in this subtype, the TP53 pathway is frequently
altered via MDM2, MDM4, or CDKN2A CNA events, leading to
an increased number of samples with CNA in the TP53 pathway
and thus an early placement of that pathway. The lack of an
inferred order between the RAS and PIK3C1/AKT pathways
may potentially be the result of increased crosstalk between the
two pathways in this subtype: cell line experiments have shown
that while both RAS and PIK3C1/AKT pathway alteration may
be necessary to initiate cancers, either pathway alone is sufficient
to maintain tumor growth [54]. In addition, we observed that in a
subset of cases, AKT alteration was predicted to occur after RB
signaling disruption and before TP53 inactivation, representing
the reverse order of the overall temporal sequence. This finding
may be due to the accumulation of multiple mutational hits at
different times in one or more of the pathways, or due to feedback
between the gene products in the pathways. Given that the
reversed ordering had less weight than the overall order, a second
hit in a subset of samples could also potentially account for this
reversed order. For the detailed output of the orders determined
by RESIC for the mesenchymal subtype, see Text S3.
Neural and classical GBM
For samples belonging to the neural and classical subtypes of
GBM, no significant temporal sequence of pathway alterations was
Figure 3. Cluster analysis of the TCGA GBM patient data. The
stability of the clusters increases with the number of clusters and
stabilizes around four clusters. A) Consensus matrix. The entry (i, j)i n
the consensus matrix measures the proportion of iterations of
clustering in which the ith sample clusters with the jth sample.
Assuming perfect clustering, all entries (i, j) in the consensus matrix
would be either 0 or 1, representing either sample i never clustering
with sample j, or always clustering with sample j. When the samples in
the matrix are ordered according to their cluster, perfect consensus
results in a block-diagonal matrix. Note that the stability of the clusters
stabilizes at k=4. B) Consensus CDF of the entries of the consensus
matrix. With perfect clustering, all entries would be zero or one,
resulting in a CDF consisting of a flat line at the percentage of zero
entries in the consensus matrix and ending with a spike at one. The
closer the CDF approaches this limit, the better the clustering. Note that
the clustering stabilizes at k=4, with little increase afterwards. C)
Silhouette plot of the four clusters. Positive values on the silhouette
plot identify samples that most stably represent each subtype. We
exclude samples with zero or negative silhouette values to ensure only
samples that fit the subtype are used in the subtyped RESIC analyses.
doi:10.1371/journal.pcbi.1002337.g003
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which is a limited number of samples on which to perform RESIC
analyses. In addition, the neural subtype is often subject to
contamination, a finding supported by the observation that normal
tissue samples cluster together with samples of this subtype [35].
We then analyzed the 98 samples belonging to the classical GBM
subtype. Huse et al. recently found that all samples categorized as
classical GBM according to Verhaak et al. [35] can instead be split
evenly into the remaining three subtypes [55] when following the
previous classification scheme by Philips et al. [34]. Thus, for this
subtype, we expected to detect an even distribution of temporal
orderings corresponding to the other subtypes. Indeed, we found
no significant temporal orderings of events, but an even
distribution of the flow through the mutational network (see Text
S4 and S5).
RESIC identifies distinct temporal sequences of genetic
alterations for GBM
After determining the order of pathway alterations both in all
GBM samples and in specific subtypes, we sought to establish the
temporal sequence of specific genetic alterations underlying these
pathway alterations. We identified all correlated alterations within
the TCGA dataset with a p-value of 0.05 and analyzed the results
using the RESIC algorithm. We first analyzed the alterations on a
pairwise basis: if two alterations were correlated, we performed a
RESIC analysis on the pair and determined the relative order of
the two alterations. We then combined all relative orderings into a
single network (see Methods). In these analyses of genetic
alterations, there was no instance in which one alteration was
placed early by one analysis but late by another analysis,
demonstrating consistency between the results despite the
assumption of independence between individual analyses
(Figure 5A). Additionally, our results involving EGFR and PTEN
correspond closely to the findings obtained previously [24]: we
found a loss of significance of the ordering when only CNA data
was included, resulting in frequencies of 43.5% versus 46.3% for
the flux with PTEN before EGFR and low level amplification of
EGFR before PTEN loss, respectively, which is consistent with our
current results of 43.8% versus 45.9%. We did, however, obtain a
result that was not consistent with the progression of events
inferred from secondary glioblastomas: PTEN loss was placed
early in our analyses while in secondary GBMs, PTEN loss tends
to occur late, rarely occurring in astrocytomas; in contrast, PTEN
alterations are prevalent in GBMs [56]. This result may be due to
differences in progression between primary and secondary
gliomas.
Additionally, in contrast to our pathway-driven analyses, we
found that many of the resulting orderings were weaker when
using individual gene-based analyses (Figures 2 and 5). For
example, in pathway-based analyses (Figure 2), four out of the six
temporal orderings were determined to occur with more than 70%
frequency as well as in 100% of all bootstrap iterations. In
contrast, in gene-based analyses (Figure 5), only four of ten
temporal orderings occurred with more than 70% frequencies and
in less than 100% bootstrap iterations. This difference exposes the
additional level of noise that gene-based approaches encounter
due to the similarity of the effects of mutations within genes
Figure 4. Temporal sequence of pathway alterations within subtypes. The classical and neural subtypes did not result in any significant
orderings of pathway alterations. Mutations included as alterations of each pathway are defined in Table 1. Each arrow indicates the order in which
the two alterations arise. The first number represents the frequency with which the displayed temporal sequence occurs. The second number
represents the percent of all bootstrap iterations in which the order determined acts as the dominant temporal sequence. A) The proneural subtype.
B) The mesenchymal subtype.
doi:10.1371/journal.pcbi.1002337.g004
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placement of PTEN in the AKT/PIK3C1 pathway, many of the
orderings determined at the pathway level were the same at the
gene level. However, in gene-based analyses, the true orderings
can be obscured by the fact that multiple genes are involved in
each pathway. Other consistencies between pathway- and gene-
level analysis include RB pathway alteration through RB deletion
occurring before P53 pathway inactivation through MDM4 and
before PIK3C2 pathway inactivation through PIKC2B, RAS as
an earlier event through EGFR amplification, and TP53 mutation
arising before PIKC2B (Figure 5).
We then aimed at investigating the robustness of the RESIC
results to inclusion of further genomic alterations into each
individual analysis. Addition of further alterations may perturb the
ordering determined in the pairwise RESIC analysis by providing
an alternative set of paths through the network. That is, while the
total numbers of patient samples harboring unmutated cells, low-
level alteration, and high-level alterations remain the same, these
numbers are distributed among a larger number of mutational
states due to the inclusion of further alterations in the network. If a
significant fraction of the flux through the network is then diverted
to one particular mutational state, then the predicted order of
events might change. In principle, to determine the most accurate
sequence of events in cancer progression, all alterations involved in
tumor development would need to be included in a single RESIC
analysis. However, such an analysis is infeasible: combinatorial
expansion of the number of mutational states precludes the
existence of a sufficiently large number of samples to populate a
significant fraction of the mutational states. Instead, to test the
effects of including additional alterations on the obtained RESIC
results, we performed three-way RESIC analyses on the full
TCGA data set. We thereby independently tested the effect of
including every additional alteration correlated with the pair of
alterations investigated in the pair-wise analyses. We found that in
all cases in which a single temporal sequence of events arises at
least 58% of the time at the pair-wise gene level, the results were
stable between pair-wise and three-way analyses and thus
unaffected by the addition of further alterations to the analysis
(Figure 5B). In some cases, notably for networks of EGFR and
TP53 and networks of RB and MDM4/PIK3C2B, the order of
events remained constant between pairwise and three-mutation
analyses; however, an additional alteration was placed in between
these changes. Thus, an additional temporal ordering was
determined by using three-mutation analyses (Figure 5B).
Subtype-specific RESIC analyses of somatic alterations
Since we detected differences between the GBM subtypes when
analyzing the temporal order of alterations of signaling pathways,
we expected those differences to also appear at the genetic level.
Thus, we analyzed the subtype-specific sequence of somatic
genomic alterations. Due to the small sample numbers, the
temporal order of alterations within subtypes could be determined
in only a few cases (Figure 6). Consistent with results obtained
using the pathway-based approach, we obtained no significant
temporal orderings for samples belonging to the classical subtype.
By contrast, for samples of the neural subtype, we obtained
significant orderings of somatic alterations (Figure 6A). However,
the frequency of the dominant temporal sequence for those cases
was only slightly greater than 50%, suggesting that these findings
were not robust. Indeed, the use of Bonferroni corrected p-values
for correlations removed the significance of these results, as did the
use of three-way analyses. For samples belonging to the proneural
and mesenchymal subtypes, we detected only one significant
ordering each, both involving PTEN deletion events (Figure 6B
and C). The order determined for PTEN and CDKN2A in the
mesenchymal subtype, like the ordering found for the neural
subtype, had a flux through the network of about 50% and a p-
value for correlation of 0.05, and therefore was not significant.
The order of PTEN and CDK4 determined for samples belonging
to the proneural subtype, however, passed the threshold of 58%
flux through the network and also had a p-value for correlation of
0.02, and was therefore more likely to be significant. The lack of
significance in the analysis of the subtypes with respect to genetic
versus pathway alterations illustrates the increased ability of the
pathway-driven approach to detect the temporal sequence of
events with fewer samples.
In summary, the use of pathway information for the RESIC
analyses clarified the order of events in several ways. First,
combining mutational events into pathways allowed for the
detection of an ordering in cases in which fewer samples and
potentially conflicting genetic signals obscured any significant
ordering of events at the genetic level (Figures 4 and 6). In cases in
which an order could be determined at the genetic level, the
increased number of events often resulted in an additional level of
noise, thereby obscuring the results. In addition, using pathway
information removes some potentially incorrect orderings through
merging of specific alterations with the remaining events in the
pathway. However, the use of pathway information could also
hide clinically relevant mutational anomalies that should arise
separately from alterations of the remainder of the pathway. In our
GBM analyses, the placement of PTEN loss is such a concern.
Discussion
In this paper, we have extended the RESIC methodology [24],
originally designed to identify the temporal sequence of somatic
genetic alterations from cross-sectional tumor samples, to address
the order in which modifications of molecular signaling pathways
arise during tumorigenesis. This modification considerably
Figure 5. Temporal sequence of somatic mutations in all samples. Each arrow indicates the order in which the two alterations arise. A) Map
of the temporal order of all CNAs determined using pairwise RESIC analyses. The first number represents the frequency with which the displayed
temporal sequence occurs. The second number represents the percent of all bootstrap iterations in which the order determined acts as the dominant
temporal sequence. B) Map of all CNAs made using three-mutation RESIC analyses. We tested the effects of including additional mutations in RESIC
analyses by first testing the addition of a single mutation independently to each analysis. Investigation of further additions of mutations would
require more samples; furthermore, we would expect any epistatic effects on the order of mutations to show some level of effect from each gene
independently. Arrows in black are significant orderings, confirmed in at least 80% of the bootstrap iterations. Gold arrows are orderings found
significant by three-way interactions, but not by pairwise interactions. Thickness of lines denotes the number of interactions that maintained the
ordering. Since multiple three-gene analyses correspond to some arrows, the specific frequencies of orderings and the number of bootstrap
iterations are not displayed, although included in the Supplementary Information. The results of using two mutations per RESIC analysis (A) do not
differ significantly from the three mutation results (B). In no case is an order determined to be significant in pairwise analyses later found to be
reversed in three way analyses. Additionally, we found that most results are stable (confirmed in three-way analyses) as long as the most likely
evolutionary path through the mutational network comprises at least 58% of the flow. With the exception of the placement of PTEN of the AKT/
PIK3C1 pathway, many of the orderings determined at the pathway level are robust at the gene level.
doi:10.1371/journal.pcbi.1002337.g005
Determining the Order of Pathway Alterations
PLoS Computational Biology | www.ploscompbiol.org 10 January 2012 | Volume 8 | Issue 1 | e1002337reduced the noise compared to the use of individual genetic
alterations. Furthermore, it makes RESIC applicable to tumor
types in which individual mutations may be so infrequent that they
rarely co-occur in samples, thus leading to the absence of
statistically significant associations among events. In such cases,
a pathway-based application of RESIC groups together these
sporadic events and allows for the analysis of the temporal
sequence of events.
We have applied our methodology to primary glioblastomas
(GBMs) and have identified the temporal ordering of both
pathway-level and gene-level alterations. These investigations
were performed on the entire group of glioma samples and each
of four previously defined molecular subtypes of GBMs [35]. The
subtypes are characterized by unique RNA expression and
mutational patterns [55] and, interestingly, differed in their
chronologic acquisition of molecular events. The order of events
was clearest for the proneural and mesenchymal subgroups. This
observation was consistent with data suggesting that these two
groups are more distinct and reproducible between large
expression analyses of GBM tumor collections. Moreover, within
the proneural group, the existence of two distinct mutational
pathways is interesting given the emerging data that this subgroup
may indeed be a mixture of at least two distinguishable molecular
subtypes [55]. It is conceivable that these differences may be
explained by differences in the cell of origin of each subtype;
further work is required to determine whether these two paths of
mutational acquisition are related to the disparate clinical
behavior of this GBM subgroup, although the outcome for
GBM is quite poor in almost all cases [57].
In summary, our method allows the rational investigation of
genetic and pathway alterations arising during tumorigenesis and
will be an important tool for the field to determine the order of
acquisition of events from cross-sectional cancer databases.
Methods
Patients and tumor samples
We obtained copy number alteration (CNA), gene expression,
and sequencing data for all GBM samples for which CNA data
were available from the TCGA Data Portal at http://tcga-data.
nci.nih.gov. These samples were collected and processed by the
TCGA Biospecimens Core Resource [3]. We ensured that each
sample represented a unique case by excluding all patients who
were represented in the database with multiple samples that had
different copy number results for each sample. We thus obtained
462 samples. All three data types were obtained in TCGA Level 3
format. For gene expression data, this means that all data had
been previously log-transformed and median centered, while CNA
data had been processed from microarray fluorescence amplitudes
into segmented data files. Sequencing data had been called from
amplitude data as specific indels or point mutations [3].
Descriptions of the TCGA levels can be found at http://tcga-
data.nci.nih.gov/tcga/tcgaDataType.jsp.
Detection of copy number alterations (CNAs)
In order to determine significant CNAs, we applied the GISTIC
algorithm [5] to the segmented TCGA GBM copy number data.
Independent runs of the algorithm were performed on the
complete set of samples as well as samples belonging to individual
subtypes. These analyses were run using the GenePattern analysis
software [58].
Determination of the CNA rate
We considered the accumulation of focal CNAs. Unlike whole
chromosome or chromosome arm gains or losses, these CNAs are
not caused by gross karyotypic abnormalities, likely due to
chromosomal instability [36]. Indeed, selective pressure and the
fitness effects of mutations can drive their accumulation without
the need of elevated mutation rates [36,59,60,61]. We calculated
the rate of focal copy number alterations based on a per
generation copy number alteration rate of 4.2610
25 alterations
per locus in sperm [62,63]. As previously determined, the number
of cell divisions, Nx, that sperm germ cells undergo is determined
by the following formula: Nx=30+23 (x2xp)+6=36+23 (x2xp),
where x is the age of the male and xp is the age at puberty [64,65].
Then, with an average generation of twenty years and an average
age of puberty of 13, the number of cell divisions in
spermatogenesis is on average 191. Dividing the per generation
rate by the number of cell divisions per generation, we determined
the per cell division per locus rate of CNAs as 2.2610
27,o r
1.1610
27 per allele. Coincidentally, this rate corresponds well
Figure 6. Temporal sequence of somatic mutations within
subtypes. The classical subtype did not result in any significant
orderings of genetic alterations. A) Neural subtype. B) Proneural
subtype. C) Mesenchymal subtype. In contrast to the results obtained
when using pathway alterations, we obtained no significant results
when performing gene-level analyses. In most cases, the temporal
sequences occur with less than 58% probability, meaning the results are
unlikely to remain robust to perturbation by addition of further genes.
In the neural subtype, the sole significant temporal order determined
involves PTEN loss arising before CDK4 amplification.
doi:10.1371/journal.pcbi.1002337.g006
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allele per cell division [24], and agrees with evidence that point
mutation and focal copy number alteration rates must be similar in
scale such that both mutation types are observed in similar
frequency [36]. We simplified and used m=1.0610
27 mutations
per allele per cell. In contrast, whole chromosome or chromosome
arm gains or losses are likely to arise through chromosomal
instability, and may occur at a much higher rate [36].
Gene expression-based subtyping
We used the gene expression profiling to cluster the samples into
the four subtypes of GBM using Consensus Clustering [49]
following the approach of Verhaak et al. [35]. We used the 1,740
genes in Verhaak’s gene signature as input to the Consensus
Clustering algorithm [35]. We applied hierarchical clustering with
agglomerative average linkage as the basis for Consensus
Clustering, with a distance measure of 1 minus the Pearson
correlation coefficient, and 1,000 iterations with a sub-sampling
ratio of 0.8. As the Consensus Clustering algorithm requires as
input the number of clusters, k, in which to place the samples, we
chose 4 clusters [33,34,35], but tested k=2 to 10 clusters. We
observed increasing stability of clusters via graphical examination
for increasing k until k=4 clusters (Figure 3A and B), but no
significant gain in stability afterwards. Once the clusters were
determined, we used the silhouette method to restrict the samples
used to only those with positive silhouette widths (Figure 3C).
Silhouette width is defined as the ratio of each sample’s average
distance to all other samples in the same cluster and the average
distance to all other samples [50]. Thus, those samples with
positive widths are more closely related to the samples within the
cluster than the samples outside the cluster, and are likely to reside
in the correct cluster. The R package Silhouette was used to
determine silhouette widths [66].
Determination of pathway events
Mutations in several different genes can result in phenotypically
similar results. Indeed, network analyses of TCGA GBM samples
have detected a tendency for alterations to occur in specific
functional modules instead of particular genes [31]. Investigators
of the TCGA project defined a set of genes commonly mutated in
TCGA glioblastoma samples and mapped them into commonly
altered GBM signaling pathways [3,31,32], visually depicted in
Supplementary Figures 7 and 8 of [3]. Specifically, they mapped
the CNAs and point mutations commonly found in the TCGA
GBM dataset onto a manually generated network diagram of
glioma genetics gleaned from Furnari et al. [67]. We opted to use
this classification of pathways for several reasons: first, the set of
pathways was designed using the TCGA dataset and is specific to
GBMs; it thus provides greatest specificity and applicability to the
sample set we investigated. Second, the pathways were manually
curated from the glioma literature [67], ensuring as much
accuracy in the pathways as currently possible. Finally, the
directionality of the effect of each mutation could be inferred from
this definition of pathways. Manually curated pathways are not the
only option: pathway software such as Ingenuity IPA (http://
www.ingenuity.com) or BioPax [68] can identify the common
pathways in a given dataset based on databases of known gene or
protein interactions. However, these pathways would not be as
specific to GBM data, especially TCGA data, as the pathway
definition used by the TCGA consortium itself. The pathways may
also harbor inaccuracies due to limitations of software parsing of
interactions. Finally, computer-generated pathway definitions tend
to lack the directionality of the effects of mutations. Knowledge of
whether a particular mutation will increase rather than decrease
signaling in a pathway simplifies the analysis.
Using the TCGA classification as a first level approximation
for sets of genes with similar phenotypic effects, we split genes
according to those signaling pathways (Table 1) [31,32]. We
then determined whether a specific alteration in a gene would
result in an increase or decrease in signaling downstream of the
gene. While in this particular pathway definition, the direction-
ality of effect of mutations is known, it is possible to perform a
similar analysis without such information. Should the pathway
information available not include whether a given mutation
increases or decreases pathway signaling, as is the case with
many pathway databases like Ingenuity or Biopax, we assume
that the more frequent alterations of any given gene (e.g.,
amplification or deletion) result in a pro-tumorigenic effect on
cells, as functional mutations detrimental to cancer progression
are unlikely to occur frequently. However, inferring network
and pathway information may introduce further errors, as
pathway events may be wrongly defined. Thus, if non-
directional pathway information is used, caution is needed to
ensure maximum accuracy.
We considered a single alteration event occurring within any of
the genes in the network to be sufficient to result in a change in
signaling of that pathway. Since only focal copy number
alterations were considered, and since in most cases, alterations
within a signaling pathway reside on separate arms of different
chromosomes, we considered the first mutational hit on each gene
to be independent of all other mutations in the pathway. Thus, a
particular pathway alteration had a mutation rate equivalent to
Mm, where M is the number of genes involved in the pathway and
m is the per gene mutation rate. In a similar manner, the TCGA
copy number alteration data [3] was transformed into pathway
alteration data by considering a positive alteration status as having
one or more mutations that increased pathway signaling, a
negative alteration status as having one or more mutations that
decreased signaling down the pathway, and a neutral status when
no mutations within the pathway occurred.
Selection of biologically relevant genomic alterations
We restricted the set of genes related to GBM development to
those that were defined in the pathway diagram in [31,32]. The
list of genes considered for analysis is provided in Table 1.
Calculation of the pairwise temporal order of events
through RESIC analyses
We used the RESIC methodology [24] for the calculation of the
order of genomic events in cancer. RESIC considers an initial
population of N cells at risk of accumulating the genetic changes
leading to cancer. These cells proliferate according to the Moran
process [25], a stochastic process in which a cell is chosen in
proportion to its fitness to divide. Each division results in two
daughter cells, one of which replaces the original cell and the other
replaces a randomly chosen cell. During each division, one of the
daughter cells may accumulate a mutation. The lineage of a
mutated cell can then take over the population (i.e. reach fixation)
or go extinct due to stochastic fluctuations. This Markov process is
used to describe the dynamics of mutation accumulation in a
population of cells, for each patient.
Depending on the fitness values of the various combinations
of potential mutations, each path through the network of
mutations may have a different likelihood of occurring. The
Markov process described above can then be used to calculate
the transition rates between individual mutational states, and
thus the likelihood of each path through the network. This
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patients, each harboring a population of cells at risk of
accumulating mutations. The scaling from this micro-model
(on the level of a population of cells within a single patient) to
the macro-model (on the level of a population of patients, each
with a population of cells proliferating according to this
stochastic process) is obtained by multiplying the transition
rates between mutational states within one patient by the
number of patients in each mutational state. We considered the
dynamics of patients in steady state: there is a constant influx
into the unmutated state and an equal constant outflux from the
fully mutated state, accounting for diagnosis of the disease
(influx) and deaths of patients or their cure (outflux). These
parameters are selected to ensure that fitness values are within
biologically meaningful ranges, ie. that a single mutation does
not confer too large a fitness effect to be biologically
implausible. According to this model, patients enter the system
in an unmutated state and then accumulate the mutations of
interest. This starting point could be late during tumorigenesis,
if the mutations of interest are late events, or pre-cancerous if
the mutations of interest are initiating events; either way, since
t h ep r e d i c t i o n so ft h em o d e la r ec o m p a r e dt od a t ao fp a t i e n t s
after diagnosis of their disease, this starting point in the model is
also after diagnosis of the disease. Note that small influx values
into other mutational states, representing diagnosis with a
different set of alterations, does not significantly alter the
results.
At steady state, the population is distributed across all possible
states; this steady state distribution can then be compared to the
numbers of clinical samples with the corresponding genotypes,
where the total number of patients in a dataset is equal to the sum
of patients in all states. Since all samples analyzed are collected
from patients after diagnosis of their disease, the earliest time point
identifiable using such datasets is the time of diagnosis. As outlined
above, this definition does not imply that the first mutation arose
exactly at the time of diagnosis: since the event resulting in patients
entering the system is diagnosis, and all considered events are
observable in the patient samples, many events arise prior to
diagnosis. This mapping is used to optimize a subset of parameters
in the Markov process model (i.e. the fitness values of cell types) by
minimizing the difference between the prediction and the
observed frequencies in the dataset. Other parameters, such as
cellular population size, mutation rate and influx rate, are
estimated from experimental results [36,69] and tested for
robustness over several orders of magnitude [24]. The output of
RESIC is given as percent of the flux through the network via each
particular path. We found previously that within multiple orders of
magnitude, changes in the population size, mutation rates, and in-
and out-flux values have little influence on either the relative order
of the fitness values determined for each combination of
mutations, or the final percent flux through each evolutionary
trajectory.
Similarly, Beerenwinkel et al. found that the selective advantage
of mutations has the largest effect on the evolutionary dynamics of
tumorigenesis [70]. While their model was designed using the
Wright-Fisher stochastic process rather than the Moran process in
our model, both of our approaches found that changes in
population size and mutation rate alter the absolute fitness values
necessary to result in the same trajectory towards cancer [24,70].
Thus, there is a dependence on the dynamics of the system onto
parameters such as the fitness values of cells harboring particular
combinations of alterations. In our model, these changes in fitness
values, however, are so small that they still result in similar results
for the temporal sequence of mutations [24].
Determination of independent temporal sequences of
events
We applied the RESIC methodology [24] to the set of events of
interest (gene-based or pathway-based, subtyped samples or total
sample set). We determined the level of correlation between all
altered pathways using Fisher’s Exact Test. Positive correlation is
required to ensure that events co-occur sufficiently frequently to
allow for a determination of the temporal sequence. Applying a p-
value cutoff of 0.05, we identified all significantly correlated
pathway alterations and performed RESIC analyses on each pair
of correlated altered pathways. We used the following set of
parameters: the mutation rate was set to m=2.0610
27 per gene in
the pathway per cell division and the stem cell population size per
niche was set as N=100. This choice of value for N was made for
computational speed; we had previously found that an order of
magnitude variation in this parameter value results in robust results
[24]. As the RESIC algorithm is stable to order of magnitude
changes in the mutation rate as well [24], these parameter choices
led to robust results. A particular order of alterations was considered
significant if at least 80% of all bootstrap iterations resulted in the
same dominant sequence. The bootstrapping procedure was
performed independently for each analysis. In each analysis, we
took our original data set of N patients and then obtained a
bootstrapsampleofsize Nbyusingsamplingwithreplacementfrom
the counts of patients with each potential combination of mutation.
We performed 10,000 bootstrap iterations per analysis. We then
applied the RESIC algorithm on the bootstrap sample to determine
the temporal sequence of events given the bootstrapped patient
population. The bootstrap percentage for a given order of events is
the percent of all bootstrap iterations in which a given order of
events is the most likely order of events. The frequency of a given
orderofeventsdisplayed inour figures isthe average frequencyover
all bootstrap iterations.
Validation of robustness of the results to exclusion of
point mutation rate
We applied the RESIC methodology to the 145 TCGA patient
samples for which CNA and point mutation data was available.
We analyzed two sets of data: the dataset including CNA only, and
the dataset containing CNA and point mutation date. We
analyzed both datasets through our pathway-based approach as
well as the gene-based approach using pairwise and three-way
analyses. We compared the resulting temporal orderings, consid-
ering the order to be consistent between the two data types when
the percent flux through the mutational diagram varied by no
more than three and the dominant temporal sequence remained
dominant. We considered an ordering to be weakened if either
fewer alleles of a gene could be analyzed, the percent flux
decreased by more than three, or a pair or triplet of events could
no longer be analyzed when using CNA data only. We considered
an ordering to be inconsistent if the dominant temporal order
changed between the two analyses, or if an ordering could be
determined when using CNA data only, but not when using CNA
and point mutation data.
Combining individual RESIC analyses to determine the
overall sequence of events
In pair-wise analyses, the temporal order of all alterations can be
determined simply by combining the pairs of genetic or pathway
alterations in the predicted order. For example, if mutation A arises
before mutation B, and mutation C arises before mutation A, the
order of events is CRARB. Figure S1 depicts all possible
combinations of pairs of mutations that result in a three-mutation
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cannot be done simply by combining the sets of genes involved,
since there may be overlap between the results. Instead, we built
upon the pair-wise results we had determined first and then overlaid
the three-way results. Pair-wise orderings of genes that were
confirmed in multiple three-way analyses represent stable temporal
sequences of events. The resulting temporal ordering of all
mutations, with thicker lines for pairs of genes for which multiple
analyses confirmed the same order, is shown in Figure 6B.
Supporting Information
Figure S1 Pairwise comparison of three genes results in an
ordering of all three genes. We perform pairwise comparisons
between alterations to determine the overall order of events. Here
we depict all possible combinations of two pairwise orderings that
can result in a single linear order of events. We denote the three
events A (in red), B (in blue), and C (in green). Black arrows denote
the determined orders and gray arrows denote the set of pairwise
orderings that result in a three-event order.
(EPS)
Text S1 RESIC analysis results for all GBM samples. The results
from the pairwise, three-way, and pathway-based RESIC analyses
are displayed.
(TXT)
Text S2 RESIC analysis results for GBM samples belonging to
the proneural subtype. The results from the pairwise, three-way,
and pathway-based RESIC analyses are shown.
(TXT)
Text S3 RESIC analysis results for GBM samples belonging to
the mesenchymal subtype. The results from the pairwise, three-
way, and pathway-based RESIC analyses are displayed.
(TXT)
Text S4 RESIC analysis results for GBM samples belonging to
the neural subtype. The results from the pairwise, three-way, and
pathway-based RESIC analyses are shown.
(TXT)
Text S5 RESIC analysis results for GBM samples belonging to
the classical subtype. The results from the pairwise, three-way, and
pathway-based RESIC analyses are shown.
(TXT)
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